首页> 美国卫生研究院文献>Current Controlled Trials in Cardiovascular Medicine >Oral versus intravenous antibiotics for patients with Klebsiella pneumoniae liver abscess: study protocol for a randomized controlled trial
【2h】

Oral versus intravenous antibiotics for patients with Klebsiella pneumoniae liver abscess: study protocol for a randomized controlled trial

机译:肺炎克雷伯菌肺脓肿患者的口服与静脉内抗生素治疗:一项随机对照试验的研究方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundKlebsiella pneumoniae liver abscess is the most common etiology of liver abscess in Singapore and much of Asia, and its incidence is increasing. Current management includes prolonged intravenous antibiotic therapy, but there is limited evidence to guide oral conversion. The implicated K1/K2 capsule strain of Klebsiella pneumoniae is almost universally susceptible to ciprofloxacin, an antibiotic with high oral bioavailability. Our primary aim is to compare the efficacy of early (< one week) step-down to oral antibiotics, to continuing four weeks of intravenous antibiotics, in patients with Klebsiella liver abscess.
机译:背景技术肺炎克雷伯氏菌肝脓肿是新加坡和亚洲大部分地区最常见的肝脓肿病因,其发病率正在上升。目前的治疗方法包括延长静脉抗生素治疗,但指导口服转换的证据有限。涉及的肺炎克雷伯菌K1 / K2胶囊菌株几乎普遍对环丙沙星(一种具有高口服生物利用度的抗生素)敏感。我们的主要目的是比较早期(<1周)降压对口服克雷伯氏菌肝脓肿患者口服抗生素,与连续4周静脉使用抗生素的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号